Ethereum's upcoming Glamsterdam upgrade passed its private devnet test and is scheduled for a public testnet on October 6, 2026, with a mainnet launch expected in Q4 2026. The upgrade will nearly triple the block gas limit from 60 million to 200 million and reduce transaction fees by about 78.6%. Key features include enshrined proposer-builder separation to reduce reliance on third-party MEV relays and block-level access lists to enable safer, parallel transaction execution. This upgrade is part of Ethereum's Surge roadmap phase, focusing on scaling Layer 1 to improve overall network capacity and support Layer 2 rollups more efficiently.
Ethereum's Glamsterdam upgrade news comes as 46 of 50 major cryptocurrencies on Pluang rose today. For readers following crypto markets, here is Pluang's snapshot as of Sep 17, 2026 20:23 WIB: SXP fell 46.27% to Rp37, COTI rose 14.73% to Rp341 with 63% sell orders, and UNI rose 11.53% to Rp123.975 with 82% sell orders. This breadth shows strong gains across most assets today.
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Nvidia announced a nearly $10 billion investment plan to support Europe's AI ecosystem, focusing on four German startups: Agile Robots, Avelios Medical, Mirelo, and Reflex Aerospace. This move aligns with Germany's goal to lead in industrial AI, with...
Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging ...
